这项研究评估了β受体阻滞剂治疗与诊断为心力衰竭(HF)的患者住院死亡率之间的关系。
对来自重症监护医疗信息集市(MIMIC)-IV数据库的9,968名HF患者进行了回顾性队列研究。采用倾向评分匹配(PSM)来平衡基线差异。多变量回归分析用于评估β受体阻滞剂治疗对院内死亡率的影响。
■在9,968名患者中,6,439(64.6%)是β受体阻滞剂使用者。匹配之前,总体住院死亡率为12.2%(1,217/9,968).在PSM之后,共有3,212例患者配对成功.分析显示β受体阻滞剂治疗与降低住院死亡率之间存在相关性(比值比0.51[0.43-0.60],P<0.001),以及较短的Los(住院时间)医院(β-1.43[-1.96~-0.09],P<0.001)。值得注意的是,长效β受体阻滞剂治疗与住院死亡率风险降低相关(比值比0.55[0.46-0.65],P<0.001)和较短的洛杉矶医院(β-1.21[-1.80~-0.63],P<0.001)。相反,研究结果未显示住院死亡率显着下降(比值比0.66[0.44-1.01],P=0.051)或洛杉矶医院(β-1.01[-2.2~-0.25],P=0.117)与短效β受体阻滞剂治疗相关。
■重症监护病房的β受体阻滞剂治疗在降低HF患者住院死亡率风险和缩短住院时间方面具有潜在益处。具体来说,长效β受体阻滞剂通过显著降低院内死亡率和Los医院均表现出保护作用.相反,在接受短效β受体阻滞剂治疗后,本研究未观察到对该队列患者的住院死亡率或Los住院时间有实质性影响.
UNASSIGNED: This study assessed the relationship between β-blockers treatment and in-hospital mortality among individuals diagnosed with heart failure (HF).
UNASSIGNED: A retrospective cohort study was carried out on 9,968 HF patients sourced from the Medical Information Mart for Intensive Care (
MIMIC)-IV database. Propensity score matching (PSM) was employed to balance the baseline differences. A multivariate regression analysis was utilized to evaluate the impact of β-blockers therapy on in-hospital mortality.
UNASSIGNED: Among the 9,968 patients, 6,439 (64.6%) were β-blockers users. Before matching, the overall in-hospital mortality rate was 12.2% (1,217/9,968). Following PSM, a total of 3,212 patient pairs were successfully matched. The analysis revealed a correlation between β-blockers therapy and decreased in-hospital mortality (odds ratio 0.51 [0.43-0.60], P < 0.001), as well as shorter Los (length of stay) hospital (β -1.43 [-1.96∼-0.09], P < 0.001). Notably, long-acting β-blockers treatment was linked to a decreased risk of in-hospital mortality (odds ratio 0.55 [0.46-0.65], P < 0.001) and a shorter Los hospital (β -1.21 [-1.80∼-0.63], P < 0.001). Conversely, the research results did not show a notable decrease in-hospital mortality (odds ratio 0.66 [0.44-1.01], P = 0.051) or Los hospital (β -1.01 [-2.2∼-0.25], P = 0.117) associated with short-acting β-blocker therapy.
UNASSIGNED: β-blockers therapy in the intensive care unit demonstrates potential benefits in lowering the risk of in-hospital mortality and reducing the duration of hospitalization among patients with HF. Specifically, long-acting β-blockers exhibit a protective effect by significantly decreasing both in-hospital mortality and Los hospital. Conversely, the study did not observe a substantial impact on in-hospital mortality or Los hospital duration in this cohort of patients following the administration of short-acting β-blockers.